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Abstract  
Objective: This study examined the clinical utility and precision of routine screening 
for alcohol and other drug use among women attending a public antenatal service. 
Study design: A survey of clients and audit of clinical charts. 
Participants and setting: Clients attending an antenatal clinic of a large tertiary 
hospital in Queensland, Australia, from October to December 2009. 
Measurements and findings: Data were collected from two sources. First, 32 women 
who reported use of alcohol or other drugs during pregnancy at initial screening were 
then asked to complete a full substance use survey. Second, data were collected from 
charts of 349 new clients who attended the antenatal clinic during the study period. 
Both sensitivity (86%, 67%) and positive predictive value (100%, 92%) for alcohol 
and other drug use respectively, were high. Only 15% of surveyed women were 
uncomfortable about being screened for substance use in pregnancy, yet the chart 
audit revealed poor staff compliance. During the study period, 25% of clients were 
either not screened adequately or not at all.  
Key conclusions and implications for practice: Despite recommended universal 
screening in pregnancy and the apparent acceptance by our participants, alcohol and 
other drug (A&OD) screening in the antenatal setting remains problematic. 
Investigation into the reasons behind, and ways to overcome, the low screening rate 
could improve health outcomes for mothers and children in this at-risk group. 
Targeted education and training for midwives may form part of the solution as these 
clinicians have a key role in implementing prevention and early intervention 
strategies.  
Key words: Pregnancy; Alcohol and Other Drug Use; Clinical Assessment Tools; 
Prenatal Care.  
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Introduction  
Background 
In Australia, alcohol and drug misuse is associated with significant morbidity 
and mortality (Higgins, 2000; New South Wales Department of Health, 2006). 
Indeed, it is estimated that around one in five Australians over the age of 14 years 
recently consumed alcohol at risky levels, and around one third of people aged 18–29 
years had recently used illicit drugs (Australian Institute of Health and Welfare, 
2006). The literature also suggests that, although many women are motivated to 
abstain from alcohol and other drugs during pregnancy, a concerning number continue 
to use during pregnancy and whilst breast feeding (Chang et al., 1999).  
Alcohol and other drug use during pregnancy has been associated with a 
number of adverse maternal and neonatal outcomes. For example, studies suggest that 
exposure to cocaine and heroin during pregnancy is associated with higher rates of 
foetal distress, retarded growth and with premature births while alcohol use is 
associated with facial anomalies and intellectual impairment (Mayes and Carroll, 
1996; Coghlan et al., 1999; Burns et al., 2006). Neonatal outcomes may also be 
associated with differences in metabolic processes that are related to a history of 
maternal drug use, including tobacco, maternal eating and sleeping patterns and 
general health status (Burns et al., 2006).  
Alcohol and other drug use after birth has also been linked with negative 
health outcomes for children. Specifically, children of parents with substance use 
disorders are more likely to suffer maltreatment. Indeed, the proportion of ‘family 
violence’ cases in which substance misuse was a primary factor increased from 27% 
in 1996–97 to 41% in 2000–01 (McGlade et al., 2009). Harmful levels of parental 
substance use have also been linked to an impaired sense of responsibility and 
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decreased emotional regulation, and, therefore, an increased potential for aggression 
and violence among parents (Ammerman et al., 1999; Dawe et al., 2007).  
 
Management of alcohol and other drug use in pregnancy 
The literature highlights limitations in the current provision of services for 
women using alcohol and other drugs during pregnancy. These limitations may be 
associated with late presentation at antenatal services, poor retention of pregnant 
substance users in antenatal care, the nature of educational material on substance use 
that is provided to pregnant women and their partners and the adequacy of antenatal 
screening for substance use (Burns et al. 2006; Saitz et al., 2006).  
Screening for use of alcohol and other drugs in pregnancy is an important part 
of prevention. Several studies suggest that screening for alcohol consumption before 
pregnancy predicts alcohol use in the antenatal period (Chang et al., 2006; Saitz et al., 
2006). Other studies suggest that maternal alcohol consumption is influenced by the 
alcohol consumption of male partners (Leonard and Mudar, 2003), and that current 
smoking status can identify women likely to use alcohol or other drugs during 
pregnancy (Saitz et al., 2006). These findings highlight the need for comprehensive 
screening for the use of tobacco, alcohol and other drugs in the antenatal setting.  
Given the poor health outcomes reported for mothers and babies who are 
exposed to alcohol and other drugs during pregnancy and after birth, investment in 
comprehensive screening, prevention, management and care programs for this 
population is critical (Ammerman et al., 1999). Indeed, the introduction of maternity 
drug services and midwives for drug liaison has produced benefits for drug-using 
women, their newborn babies and the broader health care system (Scully et al., 2004; 
Toner et al., 2008). Unfortunately, screening for alcohol and other drugs in the 
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antenatal setting remains problematic, with clinicians often reluctant to address 
substance use with pregnant women (Saitz et al, 2006). Clinicians may not discuss 
substance use in pregnancy because they are unable to manage affirmative responses. 
At the same time, pregnant women may also be hesitant to disclose for fear of 
negative repercussions (Saitz et al, 2006). Clearly, further research is needed to assess 
the benefit of brief antenatal interventions in this high-risk group.   
 
Screening tools for alcohol and other drug use 
In June 2008, a screening instrument called the Alcohol Use Disorders 
Identification Test – C (AUDIT-C) was introduced into public antenatal services 
throughout Queensland, Australia. The purpose of the AUDIT-C was to allow 
consistency in data collection across various antenatal settings and to more accurately 
identify substance use in pregnant women, thereby allowing more opportunities for 
early intervention. The AUDIT-C is a shortened version of the full AUDIT 
instrument; that is, it is comprised of three of the ten AUDIT items. The shortened 
audit is an effective screening tool to identify harmful or hazardous drinking in the 
primary care setting, and is one of two screening instruments recommended for use in 
pregnant women (Gordon et al., 2001; Dawe et al., 2002). The brief nature of the 
questionnaire also enables busy clinicians to accurately detect patients who consume 
alcohol at hazardous levels (Piccinelli et al., 1997).  
 
Study aim 
In light of the above, this study was designed to assess the clinical utility and 
precision of the routine screening instrument for use of alcohol and other drugs 
among women attending public antenatal services in a large tertiary hospital.  
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Methods  
Ethical approval and participants 
Ethical approval for the study was granted from the local Hospital District and 
University Ethics Committees prior to commencing data collection. Participants in the 
study attended the antenatal clinic in a large tertiary hospital in Queensland, Australia. 
Data were collected from two sources: first, all new clients of the antenatal clinic who 
self-identified during screening as having used alcohol or other drugs (n = 36) were 
invited to answer a further survey about their substance use; and second through an 
audit of the clinical charts (case notes) of new clients (n = 349) of the antenatal clinic 
during the study period (October–December 2009).  
 
Survey instrument and administration 
The survey was designed to provide an accurate estimate of the frequency and 
patterns of alcohol and other drugs use in the 12 months preceding pregnancy and 
after pregnancy diagnosis. The survey included: (a) a full AUDIT, which is the 10-
item screening tool developed by the World Health Organisation (WHO) to detect 
hazardous and harmful consumption of alcohol (Saunders et al., 1993); (b) several 
items about tobacco and illicit drug use; (c) several open-ended questions about 
changes in patterns of substance use since pregnancy diagnosis; and (d) questions to 
measure the women’s perceived comfort with screening.  
The full survey data was then compared to clinical assessment data to 
determine the extent to which the screening instrument was able to accurately predict 
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the sensitivity and positive predictive value (PPV) of substance use in this 
population.1 The formulae for calculating sensitivity and PPV are outlined below:  
 True disease state  
Result of the screening test Positive Negative  
Positive a b a+b 
Negative c d c+d 
 a+c b+d  
Sensitivity = a/a+c 
Positive predictive value = a/a+b 
  Due to limitations in the study design, it was not feasible to conduct surveys 
with patients who screened negative and therefore the specificity or the negative 
predictive value for the screening test was not calculated.  
The survey was administered by a registered midwife between October and 
December 2009. In the event that participants disclosed information not identified 
during the initial screening, the midwife provided appropriate information, resources 
and referral. Within this clinical setting, women who disclose use of alcohol and other 
drugs (e.g. those who have injected drugs in the past 12 months, regularly use 
cannabis or amphetamines, binge drink or are not responsive to behavioural change 
during pregnancy) are referred to a specialist maternity substance use clinic. Any 
additions to participants’ clinical management were documented in their charts.  
During the study period, 36 women identified as having used alcohol or other 
drugs and were invited to participate in the survey. Of these, 32 provided data (a 
                                                 
1 The sensitivity of a screening test refers to its ability to correctly identify those who have the 
condition (Gordis, 2004) while positive predictive value refers to the proportion of people with a 
positive test who actually have the condition (Gordis, 2004). 
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response rate of 89%), 2 women declined to participate in the study and 2 women who 
initially agreed to participate were unable to be contacted on two separate occasions. 
During data entry, incomplete data in the screening instrument was noted in 
the charts of some survey participants. Specifically, the history of drug use was 
incomplete in 14 charts, and the section on alcohol consumption was not completed in 
one instance. In these cases, data were coded to indicate that the women had 
responded negatively to substance use.  
The examination (audit) of the charts of all new clinic clients recorded 
compliance with the screening instrument and provided demographic data for all 
participants. Consent to review the charts was obtained from women at their initial 
admission by asking them to sign a Consent to Participate in Research form as part of 
their paperwork. Charts were reviewed for information on age, place of birth, 
languages spoken at home, marital status, parity and weeks of gestation. Also noted 
was whether the screening instrument had been offered to the woman and, if so, was 
completed. A total of 349 new clients (including the women who screened positive) 
attended the antenatal clinic during the study period and provided chart data for 
analysis.  
 
Data analysis 
Data were analysed using SPSS version 18.0 (SPSS, 2009). Data are presented 
as mean ± SD, mean + 95% confidence interval or counts and percentages. 
Differences between discrete variables were tested with Pearson Chi-Square or 
Continuity Correction (for cell counts of less than two and where Fisher’s Exact Test 
was not available). The means of normally distributed, continuous variables were 
compared with independent t-tests. The level for significance was set at α = 0.05.  
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Findings 
The socio-demographic characteristics (Table 1) and other relevant clinical 
information for the women who responded affirmatively to the screening instrument 
(and then completed the survey) and for the women who denied substance use (at 
initial presentation) were similar. The average age of women in the study was 28 
years (SD 5.8, t = -0.270, p = 0.787), the average number of pregnancies, including 
the current pregnancy, was two (SD 1.6, t = 0.285, p = 0.776) and one previous live 
birth (SD 1.1, t = -0.045, p = 0.964).  
 
INSERT TABLE 1 ABOUT HERE 
 
When the survey data of the women who identified as using substances were 
compared with their screening results, both the sensitivity and the PPV of the brief 
screening instrument was high (Table 2). The screening instrument was able to detect 
substance use in most instances (sensitivity), although the sensitivity for illicit drug 
use was lower than for alcohol and smoking (tobacco). Almost all women who 
screened positive had used alcohol or other drugs (PPV). In terms of false positive 
results, only one woman who initially reported illicit drug use during screening denied 
drug use in the full survey.  
 
INSERT TABLE 2 ABOUT HERE 
 
Patterns of substance use before and after pregnancy diagnosis 
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Further examination of the survey data revealed some differences between 
past and current patterns of substance use that were not fully detected by the screening 
instrument. Analysis of past and current use suggested that some women who had 
used alcohol or other drugs in the past had stopped using when they received a 
pregnancy diagnosis (Table 3). For example, almost half (42.4%, n = 14) of 
participants reported drinking more than weekly in the 12 months preceding 
pregnancy, compared with only 3.0% of women (n = 1) after pregnancy diagnosis (χ2 
= 21.086, p = 0.012). Women also reported a reduction in the daily number of drinks 
typically consumed after finding they were pregnant. Specifically, 57.6% of women 
(n = 19) drank more than 6 drinks on any one occasion before pregnancy, compared 
with only 6.1% (n = 2) of women after confirmation of their pregnancy (χ2 = 0.265, p 
= 0.607). Similarly, among women who reported illicit drug use, the frequency of use 
decreased after pregnancy diagnosis. For example, almost a quarter (24.2%, n = 8) of 
women reported amphetamine use in the 12 months before becoming pregnant, while 
less than one-tenth (9.1%, n = 3) of women reported continued amphetamine use after 
pregnancy diagnosis (χ2 = 6.274, p = 0.012). It should be noted that not all of these 
results reached statistical significance, however, any reduction in alcohol and other 
drug use during pregnancy could be argued as clinically significant. 
 
INSERT TABLE 3 ABOUT HERE 
 
Women were also asked some open-ended questions about the behavioural 
changes they had made since confirmation of their pregnancies. Many reported 
pregnancy as a strong motivator for either stopping or reducing their alcohol intake: 
 
  Page 11of 22  
 
 I wanted to stop everything at least while I was pregnant  
 
Had already stopped. She said "no alcohol is safe in pregnancy". So I took that on 
board with other advice from medical professionals and friends who say 1 or 2 is 
okay. 
 
I mostly stopped drinking as soon as I started trying for a pregnancy. I cut out 
completely when pregnancy confirmed 
 
Cut out drinking completely, cut out nightly cigarette as well 
 
Women who had used illicit drugs reported similar motivations:  
 
I had stopped using ecstasy anyway. Slow down cannabis. A little bit at night helps 
me stay level headed and cope with everything. I still want to reduce smoking. I have lots of 
stressors. 
 
I cut out smoking and pot as soon as I found out I was pregnant.  
 
I had already got on Subutex® and off the Oxycontin®. She [the midwife] told me there 
were people to help me at the hospital. 
 
Had already stopped when I found out I was pregnant 
 
Clinical chart audit 
The audit of clinical charts from all the new clients who attended the antenatal 
clinic during the study period showed that the screening instrument was often only 
partially completed and available in the charts (Table 4). Specifically, the smoking 
section was incomplete in almost one-third (32.2%, n = 112) of charts, the alcohol 
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section was incomplete in more than one-third (39.1%, n = 136) of charts, and the 
section on drug use was incomplete in most (93.4%, n = 324) charts.  
 
INSERT TABLE 4 ABOUT HERE 
 
Despite the relatively large proportion of incomplete data in the screening tool, 
it appeared that most of the 32 women who screened positive were amenable to being 
asked about their substance use. Indeed, over half (54.5%, n = 18) of the women 
surveyed reported feeling very comfortable being asked about their use of alcohol or 
other drugs. Only one women reported feeling uncomfortable and four very 
uncomfortable about being questioned on their substance use. Importantly, 31 of the 
32 women surveyed (93.9%) reported that they did not feel at all judged by the 
midwife who took their clinical histories.  
 
Discussion  
Our findings suggest that the screening instrument is able to accurately 
identify pregnant women who have used alcohol or other drugs. Moreover, most new 
clients of the antenatal clinic at the large Australian public hospital where our study 
was performed were open to being asked about their use of alcohol and other drugs as 
part of their initial routine screening by midwives. Importantly, few of the women 
surveyed further reported feeling judged by the midwife taking their clinical histories. 
This research apparently contradicts that of Roberts and Nuru-Jeter (2010),  
who found that many women in their study were averse to having their illicit drug use 
(but not their alcohol use) identified during antenatal screening. Moreover, the women 
in their sample distrusted clinicians and expected adverse outcomes after being 
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identified as ‘users’; for example, feelings of maternal failure, judgment and child 
protection alerts. 
Despite the women’s apparent openness about their substance use, a 
significant proportion of the women in our study were not fully screened. It may be 
that midwives are reluctant to ask women about their use of alcohol and other drugs. 
Indeed, Saitz et al. (2006) indicated that clinicians might not ask about substance use 
during pregnancy because they are unable to manage affirmative responses. The 
reluctance of clinicians to address socially sensitive or otherwise difficult topics has 
been researched in related literature. For instance, McCosker-Howard et al. (2005) 
found that midwives might have difficulty asking pregnant women about domestic 
violence, despite the prevailing belief about the value of screening. Therefore, 
midwives may need additional training in asking women ‘difficult’ questions and in 
appropriately managing those who disclose.  
The benefits of routine, universal, antenatal screening for substance use seem 
clear. For women who are identified as using alcohol or other drugs in their 
pregnancies, early intervention can improve outcomes for both mothers and neonates. 
Of course, the adverse affects of such screening must be considered. According to 
Roberts and Nuru-Jeter (2010, p. 193), screening for substance use in the antenatal 
setting may cause women to avoid or disengage from prenatal care, which could lead 
to ‘late, limited, and no prenatal care on pregnancy outcomes and missed 
opportunities for health promoting interventions.’ However, it is difficult to see how 
these same health-promoting interventions can be effectively delivered if midwives 
are unaware of the issues requiring intervention. 
The results of this study must be interpreted in light of several methodological 
limitations. First, the estimates of substance use were based on self-report; some 
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women may have underestimated, or even denied, their use because of perceived 
social unacceptability. Indeed, the social acceptability of an activity (e.g. alcohol or 
other drug use or high-risk sexual activity) can potentially influence reporting and 
lead to an underestimation of prevalence rates (Evans and Crawford, 1999; Ghanem et 
al., 2005). However, self-reporting in the clinical setting that we studied is unlikely to 
have yielded false positive results. Also, by necessity, the quality and consistency of 
the data we collected through the audit of clinical charts relied directly on information 
previously gathered by clinicians during consultations.  
Despite the limitations imposed by the method of data collection, this study 
provided an opportunity to review current clinical practices related to screening for 
substance use in the antenatal setting. The information collected allows the 
organisation to better focus the education and training of midwives working in this 
area. By developing consistent, comprehensive guidelines for the screening of 
pregnant women, midwives can more accurately identify at-risk women. The clinical 
care and health outcomes for this population can thus be improved.  
Of course, this study also raises questions about the apparent unwillingness of 
midwives to screen pregnant women for substance use. To improve health outcomes 
for mothers and children, further research should focus on overcoming this reluctance 
within maternity services to address socially sensitive or otherwise difficult topics. 
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Conclusion  
In summary, this study found that the brief screening instrument was able to 
detect most instances of substance use in the clients of an antenatal clinic in a large 
public hospital. Except for one participant, all women who screened positive had 
actually used alcohol or other drugs, according to a further survey. However, the 
screening instrument was often unable to detect changes in patterns of substance use 
since pregnancy diagnosis. In addition, the audit of clinical charts revealed that 
alcohol and other drug screening was not completed in a significant proportion cases. 
This finding may be explained by reluctance on the part of the consulting midwives to 
complete the instrument, either because they feel unequipped to manage affirmative 
responses or because they do not fully understand the importance of early 
identification and intervention. Additional targeted clinical training may improve this 
situation. In any case, investigating how to overcome this apparent reluctance could 
improve health outcomes for both mothers and children. 
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Table 1. The socio-demographic characteristics of pregnant women reporting or 
denying use of alcohol and other drugs on initial presentation at the antenatal clinic (n 
= 349)  
 Cases 
(n = 32) 
Comparison 
(n = 317) 
χ2 p  
 n (%)  n (%) 
Place of birth   
4.786 
 
0.188    Australia or New Zealand 25 (78.1) 198 (62.5) 
   Europe 3 (9.4) 23 (7.3) 
   Asia 2 (6.3) 66 (20.8) 
   Other country 2 (6.3) 30 (9.5) 
Marital status   
0.564 
 
0.754    Single 4 (12.5) 29 (9.2) 
   Married 28 (87.5) 285 (90.2) 
   Divorced or separated 0 (0) 2 (0.6) 
Occupation   
1.295 
 
0.862    Manager or professional 7 (24.1) 85 (27.7) 
   Trade or technical workers 8 (27.6) 95 (30.9) 
   Service or labourer 3 (10.3) 19 (6.2) 
   Home duties  5 (17.2) 40 (13.0) 
   Unemployed/student 6 (20.7) 68 (22.1) 
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Table 2. Precision of the alcohol and other drug screening instrument in the antenatal setting. 
 
Drug class 
 
Sensitivity  
% (95% CI) 
Positive Predictive Value  
% (95% CI) 
Alcohol consumption 85.7 (67.8–94.9) 100 (83.6–100) 
Tobacco (smoking) 90.5 (69.8–98.5) 100 (80.2–100) 
Illicit drugs 66.6 (43.6–83.9) 92.3 (64.5–99.9) 
CI = confidence interval 
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Table 3. Self-reported patterns of use of specific drugs among substance-using pregnant 
women (n = 32) 
 In the 12 months 
preceding pregnancy
During pregnancy    χ2 p 
 n (%) n (%)   
Alcohol use     
Frequency of alcohol 
consumption 
    
   Never 4 (12.1) 17 (51.5) 21.086 0.012
   Monthly or less 6 (18.2) 9 (27.3)   
   2-4 times monthly 9 (27.3) 6 (18.2)   
   More than weekly 14 (42.4) 1 (3.0)   
Typical daily alcohol 
consumption 
    
   Nil 4 (12.1) 16 (48.4) 6.010 0.198
   1-2 drinks 4 (12.1) 15 (45.5)   
   3 or more drinks 25 (75.8) 2 (6.1)   
Drinks 6 or more drinks on  
one occasion 
    
   Never 14 (42.4) 31 (93.9) 0.265 0.607a
   Ever 19 (57.6) 2 (6.1)   
Illicit drug use     
Used heroin     
   Never 31 (93.9) 32 (97.0) 3.497 0.061 a
   Ever 2 (6.1) 1 (3.0)   
Used opiates     
   Never 29 (90.6) 31 (97.0) 2.005 0.157 a
   Ever 3 (9.4) 1 (3.0)   
Used amphetamines     
   Never 25 (75.8) 30 (90.9) 6.274 0.012 a
   Ever 8 (24.2) 3 (9.1)   
Used cannabis     
   Never 22 (66.7) 27 (81.8) 5.729 0.017 a
   Ever 11 (33.3) 6 (18.2)   
Used analgesia (pain killers)     
   Never 26 (83.9) 32 (97.0) 0.876 0.349 a
   Ever 7 (16.1) 1 (3.0)   
a Continuity Correction used   
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Table 4. Completion of the screening instrument (n = 349) 
 Yes No
 n (%) n (%)
Smoking  236 (67.8) 112 (32.2) 
Alcohol  212 (60.9) 136 (39.1) 
Illicit drug use 23 (6.6) 323 (93.4) 
 
 
 
